

## Gram-Positive Bacterial Infections

[View the current Gram-Positive Bacterial Infections InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Gram-Positive_Bacterial_Infections.html) (PDF)  
([http://www.bioportfolio.com/indepth/Gram-Positive\\_Bacterial\\_Infections.html](http://www.bioportfolio.com/indepth/Gram-Positive_Bacterial_Infections.html)) - Regularly Updated.

### Recent Publications on Gram-Positive Bacterial Infections:



- [Enterococcus casseliflavus endophthalmitis associated with a horse tail injury.](#)  
*An overview of the mechanism of action, dosing, clinical indications, and...*18th November, 2009  
- Arch Ophthalmol. 2009 Nov;127(11):1551-2. ([DOI Direct Link](#))
- [Finegoldia magna: a forgotten pathogen in prosthetic joint infection rediscovered by molecular biology.](#)  
*In this study, we describe 13 patients with prosthetic infections due to...*18th November, 2009  
Unite de Recherche sur les Maladies Infectieuses et Tropicales- Clin Infect Dis. 2009 Oct 15;49(8):1244-7. ([DOI Direct Link](#))
- [Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.](#)  
*An overview of the mechanism of action, dosing, clinical indications, and...*17th November, 2009  
Department of Internal Medicine, Wayne State University, Detroit, MI- Infect Dis Clin North Am. 2009 Dec;23(4):965-82, ix. ([DOI Direct Link](#))
- [Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States.](#)  
*BACKGROUND: The Enterococcus faecium genogroup, referred to as clonal...*17th November, 2009  
Department of Internal Medicine, Division of Infectious Diseases,- J Infect Dis. 2009 Nov 15;200(10):1566-73. ([DOI Direct Link](#))
- [Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials.](#)  
*This review aimed to compare data regarding the effectiveness and safety...*11th November, 2009  
Department of Clinical Pharmacology, General Hospital of Chinese People's- Int J Antimicrob Agents. 2009 Nov 7. ([DOI Direct Link](#))
- [Future gazing in the management of multiply drug-resistant Gram-positive infection.](#)  
*Gram-positive bacteria have evolved to become predominant health care...*10th November, 2009  
Department of Microbiology, Leeds Teaching Hospitals NHS Trust and- J Infect. 2009 Sep;59 Suppl 1:S75-80. ([DOI Direct Link](#))
- [Treatment of pediatric Gram-positive multidrug-resistant infections.](#)  
*Gram-positive organisms are the most common cause of bacterial infections...*10th November, 2009  
Case Western Reserve University School of Medicine, Cleveland, Ohio- J Infect. 2009 Sep;59 Suppl 1:S51-8. ([DOI Direct Link](#))
- [Health economic issues in the treatment of drug-resistant serious Gram-positive infections.](#)  
*Escalating health care costs have stimulated a paradigm change in the way...*10th November, 2009  
Consultant Physician and Honorary Professor, Infection Unit, East Block,- J Infect. 2009 Sep;59 Suppl

- 1:S40-50. ([DOI Direct Link](#))
- [Infections caused by Gram-positive bacteria: a review of the global challenge.](#)  
*Infections caused by multidrug-resistant Gram-positive bacteria represent...*10th November, 2009  
Antibiotic Resistance Monitoring and Reference Laboratory, Centre for- J Infect. 2009 Sep;59 Suppl 1:S4-16. ([DOI Direct Link](#))
  - [Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria.](#)  
*Gram-positive aerobes are the most common organisms in hospitalized...*10th November, 2009  
Infectious Diseases Section, Veterans Administration Medical Center,- J Infect. 2009 Sep;59 Suppl 1:S32-9. ([DOI Direct Link](#))
  - [Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.](#)  
*Several new antimicrobials demonstrate in vitro activity against...*10th November, 2009  
Division of Infectious Diseases, Beth Israel Deaconess Medical Center,- J Infect. 2009 Sep;59 Suppl 1:S17-24. ([DOI Direct Link](#))
  - [New treatments for multiply drug-resistant Gram-positive bacteria.](#)  
*Several new antimicrobials demonstrate in vitro activity against...*10th November, 2009  
Harvard Medical School and Beth Israel Deaconess Medical Center, Boston,- J Infect. 2009 Sep;59 Suppl 1:S1-3. ([DOI Direct Link](#))
  - [Population-based surveillance of infectious endocarditis in an Italian region.](#)  
*This review aimed to compare data regarding the effectiveness and safety...*5th November, 2009  
- Arch Intern Med. 2009 Oct 12;169(18):1720-3. ([DOI Direct Link](#))
  - [Leuconostoc spp sepsis in an extremely low birth weight infant: a case report and review of the literature.](#)  
*A three week old extremely low birth weight (ELBW) infant infected by...*30th October, 2009  
WVU School of Medicine Department of Pediatrics, Morgantown, WV, USA.- W V Med J. 2009 Sep-Oct;105(5):24-7.
  - [\[Biofilm and bacterial microorganisms in genito-urinary infections\]](#)  
*Biofilms represent a cohesive matrix of microorganisms and other cellular...*22nd October, 2009  
Centro per le Malattie a Trasmissione Sessuale, ASL 10, Firenze, Italy.- Infez Med. 2009 Jun;17 Suppl 1:3-9.

## Gram-Positive Bacterial Infections Patents:



- 6790448- [Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them](#)
- 7109245- [Vasoconstrictor cannabinoid analogs](#)
- 7141583- [Oxazolidinone derivatives with antibiotic activity](#)
- 7141588- [N-aryl-2-oxazolidinone-5-carboxamides and their derivatives](#)
- 7157456- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7169903- [Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria](#)
- 7179794- [Multivalent macrolide antibiotics](#)
- 7195763- [Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them](#)
- 7220738- [Rifamycin analogs and uses thereof](#)
- 7250494- [Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive](#)

## [bacteria](#)

- 7271154- [Antibiotic conjugates](#)
- 7105547- [Antimicrobial 1-aryl dihydropyridone compounds](#)
- 7094900- [N-Aryl-2-oxazolidinones and their derivatives](#)
- 7081538- [Substituted isoxazolines and their use as antibacterial agents](#)
- 6833453- [Methods of producing oxazolidinone compounds](#)
- 6852689- [Methods for administration of antibiotics](#)
- 6906037- [Therapeutic peptide-based constructs](#)
- 6919329- [N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives](#)
- 6927229- [Difluorothioacetamides of oxazolidinones as antibacterial agents](#)
- 6964948- [Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein](#)
- 7002020- [Oxazolidinone combinatorial libraries, compositions and methods of preparation](#)
- 7041644- [Therapeutic uses of BPI protein products in BPI-deficient humans](#)
- 7041702- [Pharmaceutically active compounds and methods of use](#)
- 7045501- [Method of treating chronic cardiac disease](#)
- 7271165- [Rifamycin analogs and uses thereof](#)
- 7291343- [Enterococcus antigens and vaccines](#)
- 7488726- [Rifamycin analogs and uses thereof](#)
- 7494991- [Rifamycin analogs and uses thereof](#)
- 7504381- [Antimicrobial agents](#)
- 7514099- [Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- 7521073- [Compositions and methods for activating Toll-like receptor 4](#)
- 7524954- [Process for the preparation of linezolid and related compounds](#)
- 7547692- [Rifamycin analogs and uses thereof](#)
- 7576111- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7585860- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7592003- [Regulation of toll-like receptors on stem cells](#)
- 7459272- [Reduction in bacterial colonization by administering bacteriophage compositions](#)
- 7449189- [Glycoconjugate vaccines for use in immune-compromised populations](#)
- 7435751- [7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents](#)
- 7291451- [Modulation of pericyte proliferation](#)
- 7291614- [Processes for the preparation of linezolid intermediate](#)
- 7304050- [Antibacterial agents](#)
- 7307163- [Process for the preparation of linezolid and related compounds](#)
- 7322965- [Infection-resistant medical devices](#)
- 7342011- [Rifamycin analogs and uses thereof](#)
- 7348309- [Glycorandomization and production of novel vancomycin analogs](#)
- 7351824- [Process for the preparation of linezolid and related compounds](#)
- 7364719- [Vasoregulating compounds and methods of their use](#)
- 7404969- [Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- 7592339- [Substituted oxazolidinones and their use in the field of blood coagulation](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

